Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
| Revenue (Most Recent Fiscal Year) | $45.44B |
| Net Income (Most Recent Fiscal Year) | $14.85B |
| PE Ratio (Current Year Earnings Estimate) | 14.91 |
| PE Ratio (Trailing 12 Months) | 15.61 |
| PEG Ratio (Long Term Growth Estimate) | 1.63 |
| Price to Sales Ratio (Trailing 12 Months) | 4.69 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.36 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 9.89 |
| Pre-Tax Margin (Trailing 12 Months) | 22.75% |
| Net Margin (Trailing 12 Months) | 33.76% |
| Return on Equity (Trailing 12 Months) | 34.56% |
| Return on Assets (Trailing 12 Months) | 14.24% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.93 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.72 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.47 |
| Inventory Turnover (Trailing 12 Months) | 2.16 |
| Book Value per Share (Most Recent Fiscal Quarter) | $20.50 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.97 |
| Earnings per Share (Most Recent Fiscal Year) | $6.90 |
| Diluted Earnings per Share (Trailing 12 Months) | $7.41 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Common Shares Outstanding | 2.04B |
| Free Float | 2.04B |
| Market Capitalization | $224.70B |
| Average Volume (Last 20 Days) | 1.47M |
| Beta (Past 60 Months) | 0.57 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.01% |
| Percentage Held By Institutions (Latest 13F Reports) | 13.12% |
| Annual Dividend (Based on Last Quarter) | $2.43 |
| Dividend Yield (Based on Last Quarter) | 2.21% |